Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 10, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2019-09-26
DOI
10.3389/fimmu.2019.02254
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma
- (2019) Hamzah Abu-Sbeih et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- New therapeutic perspectives to manage refractory immune checkpoint-related toxicities
- (2019) Filipe Martins et al. LANCET ONCOLOGY
- Regulatory T cells mediate specific suppression by depleting peptide–MHC class II from dendritic cells
- (2019) Billur Akkaya et al. NATURE IMMUNOLOGY
- Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors
- (2019) Arielle Elkrief et al. OncoImmunology
- Clinical Outcomes of Patients with Advanced Cancer and Pre‐Existing Autoimmune Diseases Treated with Anti‐Programmed Death‐1 Immunotherapy: A Real‐World Transverse Study
- (2019) Alessio Cortellini et al. ONCOLOGIST
- A defined commensal consortium elicits CD8 T cells and anti-cancer immunity
- (2019) Takeshi Tanoue et al. NATURE
- Inflammasome activation and Th17 responses
- (2019) Jian Deng et al. MOLECULAR IMMUNOLOGY
- Impact of early inflammatory cytokine elevation after commencement of PD-1 inhibitors to predict efficacy in patients with non-small cell lung cancer
- (2019) Yuichi Ozawa et al. MEDICAL ONCOLOGY
- Realizing the Clinical Potential of Immunogenic Cell Death in Cancer Chemotherapy and Radiotherapy
- (2019) Bernardo Rapoport et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Immune-related adverse events predict the therapeutic efficacy of anti–PD-1 antibodies in cancer patients
- (2019) J. Rogado et al. EUROPEAN JOURNAL OF CANCER
- Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients
- (2019) Alessio Cortellini et al. Clinical Lung Cancer
- Multiple sclerosis outcomes after cancer immunotherapy
- (2019) Catherine R. Garcia et al. Clinical & Translational Oncology
- Gut microbiome and cancer immunotherapy
- (2019) Weina Li et al. CANCER LETTERS
- Prognostic and predictive value of an immune-related adverse event among stage III melanoma patients included in the EORTC 1325/KEYNOTE-054 pembrolizumab versus placebo trial.
- (2019) Alexander M. M. Eggermont et al. JOURNAL OF CLINICAL ONCOLOGY
- Serum IL-6 and CRP as prognostic factors in melanoma patients receiving single agent and combination checkpoint inhibition.
- (2019) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- The CANOPY program: Canakinumab in patients (pts) with non-small cell lung cancer (NSCLC).
- (2019) Luis G. Paz-Ares et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- (2019) Tony S K Mok et al. LANCET
- Pembrolizumab for all PD-L1-positive NSCLC
- (2019) Egbert F Smit et al. LANCET
- Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer
- (2019) Sha Zhao et al. LUNG CANCER
- Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial
- (2019) Leonie Voorwerk et al. NATURE MEDICINE
- The pathogenicity of Th17 cells in autoimmune diseases
- (2019) Keiko Yasuda et al. Seminars in Immunopathology
- Gut microbiota dependent anti-tumor immunity restricts melanoma growth in Rnf5−/− mice
- (2019) Yan Li et al. Nature Communications
- IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy
- (2019) Daniel Johnson et al. Cancer Immunology Research
- Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor–induced colitis
- (2019) Hamzah Abu-Sbeih et al. Journal for ImmunoTherapy of Cancer
- Exploring the emerging role of the microbiome in cancer immunotherapy
- (2019) Jessica Fessler et al. Journal for ImmunoTherapy of Cancer
- Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review
- (2019) Shaheen Khan et al. SEMINARS IN CANCER BIOLOGY
- Clonality of CD4+ Blood T Cells Predicts Longer Survival With CTLA4 or PD-1 Checkpoint Inhibition in Advanced Melanoma
- (2019) Akiko Arakawa et al. Frontiers in Immunology
- The Tolerogenic Function of Regulatory T Cells in Pregnancy and Cancer
- (2019) Nanna Jørgensen et al. Frontiers in Immunology
- Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer
- (2018) L Derosa et al. ANNALS OF ONCOLOGY
- When worlds collide: Th17 and Treg cells in cancer and autoimmunity
- (2018) Hannah M. Knochelmann et al. Cellular & Molecular Immunology
- Monoclonal Antibodies Targeting the IL-17/IL-17RA Axis: An Opportunity to Improve the Efficiency of Anti-VEGF Therapy in Fighting Metastatic Colorectal Cancer?
- (2018) Sajida Ibrahim et al. Clinical Colorectal Cancer
- Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors
- (2018) Kristian M. Hargadon et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab
- (2018) Koichi Sato et al. LUNG CANCER
- The gut microbiota influences anticancer immunosurveillance and general health
- (2018) Bertrand Routy et al. Nature Reviews Clinical Oncology
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
- (2018) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of Immune‐Related Adverse Events with Clinical Benefit in Patients with Advanced Non‐Small‐Cell Lung Cancer Treated with Nivolumab
- (2018) Yukihiro Toi et al. ONCOLOGIST
- Canakinumab and Lung Cancer: Intriguing, but Is It Real?
- (2018) Bruce A. Chabner et al. ONCOLOGIST
- Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas
- (2018) Ari Kassardjian et al. PLoS One
- The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients
- (2018) Vyara Matson et al. SCIENCE
- Brief Report: Cancer Immunotherapy in Patients With Preexisting Rheumatic Disease: The Mayo Clinic Experience
- (2018) Michael D. Richter et al. Arthritis & Rheumatology
- Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events
- (2018) Dylan J. Martini et al. Cancer Immunology Research
- Emerging Functions of Regulatory T Cells in Tissue Homeostasis
- (2018) Amit Sharma et al. Frontiers in Immunology
- Expanded Regulatory T Cells Induce Alternatively Activated Monocytes With a Reduced Capacity to Expand T Helper-17 Cells
- (2018) Marco Romano et al. Frontiers in Immunology
- The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1
- (2018) Lisa Derosa et al. OncoImmunology
- Immune Dysregulation in Cancer Patients Undergoing Immune Checkpoint Inhibitor Treatment and Potential Predictive Strategies for Future Clinical Practice
- (2018) Ronald Anderson et al. Frontiers in Oncology
- The Interleukin-17 Family of Cytokines in Breast Cancer
- (2018) Joseph Fabre et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interleukin‑17 promotes the development of cisplatin resistance in colorectal cancer
- (2018) Guolong Sui et al. Oncology Letters
- Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma
- (2018) Sabrina A. Hogan et al. Cancer Immunology Research
- The Central Role of Inflammation Associated with Checkpoint Inhibitor Treatments
- (2018) Cristina Vajaitu et al. Journal of Immunology Research
- Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study
- (2018) Nicolas Delanoy et al. Lancet Haematology
- Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity
- (2017) Ralf Gutzmer et al. EUROPEAN JOURNAL OF CANCER
- Alarmins and immunity
- (2017) De Yang et al. IMMUNOLOGICAL REVIEWS
- Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience
- (2017) Takeo Fujii et al. INVESTIGATIONAL NEW DRUGS
- IFN-γ–Expressing Th17 Cells Are Required for Development of Severe Ocular Surface Autoimmunity
- (2017) Yihe Chen et al. JOURNAL OF IMMUNOLOGY
- Myasthenia Gravis After Nivolumab Therapy for Squamous Cell Carcinoma of the Bladder
- (2017) Elaine Chang et al. JOURNAL OF IMMUNOTHERAPY
- Early Immune-Related Adverse Events and Association with Outcome in Advanced Non–Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study
- (2017) Shunsuke Teraoka et al. Journal of Thoracic Oncology
- Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade
- (2017) Esra A. Akbay et al. Journal of Thoracic Oncology
- Association of Serum Anti-GAD Antibody and HLA Haplotypes with Type 1 Diabetes Mellitus Triggered by Nivolumab in Patients with Non–Small Cell Lung Cancer
- (2017) Yuko Usui et al. Journal of Thoracic Oncology
- Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
- (2017) Paul M Ridker et al. LANCET
- Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade
- (2017) Khashayar Esfahani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
- (2017) V. Gopalakrishnan et al. SCIENCE
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
- (2017) Bertrand Routy et al. SCIENCE
- Supportive care for patients undergoing immunotherapy
- (2017) Bernardo Leon Rapoport et al. SUPPORTIVE CARE IN CANCER
- High IL-17 expression is associated with an unfavorable prognosis in thyroid cancer
- (2017) Denise Faria Galano Carvalho et al. Oncology Letters
- Antigen-specific CD8+ T cell feedback activates NLRP3 inflammasome in antigen-presenting cells through perforin
- (2017) Yikun Yao et al. Nature Communications
- CTLA-4 positive breast cancer cells suppress dendritic cells maturation and function
- (2017) Xi Chen et al. Oncotarget
- Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer
- (2017) Yuko Oya et al. Oncotarget
- Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics
- (2017) Abhishek D. Garg et al. OncoImmunology
- High frequency of intestinal T H 17 cells correlates with microbiota alterations and disease activity in multiple sclerosis
- (2017) Ilaria Cosorich et al. Science Advances
- CTLA-4 and PD-1 Pathways
- (2016) Elizabeth I. Buchbinder et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
- (2016) A. M. Menzies et al. ANNALS OF ONCOLOGY
- Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab
- (2016) Laura C Cappelli et al. ANNALS OF THE RHEUMATIC DISEASES
- Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire
- (2016) David Y. Oh et al. CANCER RESEARCH
- Myasthenic crisis and polymyositis induced by one dose of nivolumab
- (2016) Toshihiro Kimura et al. CANCER SCIENCE
- Ocular and orbital side-effects of checkpoint inhibitors
- (2016) Joëlle Antoun et al. CURRENT OPINION IN ONCOLOGY
- Autoimmune hemolytic anemia after nivolumab treatment in Hodgkin lymphoma responsive to immunosuppressive treatment. A case report
- (2016) Magalie P. Tardy et al. HEMATOLOGICAL ONCOLOGY
- Human macrophages induce CD4+ Foxp3+ regulatory T cells via binding and re-release of TGF-β
- (2016) Angelika Schmidt et al. IMMUNOLOGY AND CELL BIOLOGY
- ATP-Induced Inflammation Drives Tissue-Resident Th17 Cells in Metabolically Unhealthy Obesity
- (2016) Julieta B. Pandolfi et al. JOURNAL OF IMMUNOLOGY
- Immune-related pancreatitis secondary to nivolumab in a patient with recurrent lung adenocarcinoma: A case report
- (2016) Kazuhiko Ikeuchi et al. LUNG CANCER
- Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma
- (2016) Benjamin Y. Kong et al. MELANOMA RESEARCH
- Identifying species of symbiont bacteria from the human gut that, alone, can induce intestinal Th17 cells in mice
- (2016) Tze Guan Tan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Dendritic Cell-Secreted Cytotoxic T-Lymphocyte-Associated Protein-4 Regulates the T-cell Response by Downmodulating Bystander Surface B7
- (2016) Matthew M. Halpert et al. STEM CELLS AND DEVELOPMENT
- Revised Estimates for the Number of Human and Bacteria Cells in the Body
- (2016) Ron Sender et al. PLOS BIOLOGY
- Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab
- (2016) Camille Hua et al. JAMA Dermatology
- CTLA4 blockade reduces immature myeloid cells in head and neck squamous cell carcinoma
- (2016) Guang-Tao Yu et al. OncoImmunology
- Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors
- (2016) Belal Firwana et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Therapeutic antibodies that target inflammatory cytokines in autoimmune diseases
- (2015) Yuping Lai et al. INTERNATIONAL IMMUNOLOGY
- Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma
- (2015) Takushi Shirai et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Group 3 innate lymphoid cells mediate intestinal selection of commensal bacteria-specific CD4+ T cells
- (2015) M. R. Hepworth et al. SCIENCE
- Interleukin-17 promotes angiogenesis by stimulating VEGF production of cancer cells via the STAT3/GIV signaling pathway in non-small-cell lung cancer
- (2015) Bo Pan et al. Scientific Reports
- Promotion of lung tumor growth by interleukin-17
- (2014) Beibei Xu et al. AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
- Human CD4+CD39+regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+exosomes or CD73+cells
- (2014) P. J. Schuler et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Targeting Th17 cells in autoimmune diseases
- (2014) Jianfei Yang et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Immunotherapy of melanoma
- (2013) John B.A.G. Haanen EJC SUPPLEMENTS
- Signaling through Purinergic Receptors for ATP Induces Human Cutaneous Innate and Adaptive Th17 Responses: Implications in the Pathogenesis of Psoriasis
- (2013) M. E. Killeen et al. JOURNAL OF IMMUNOLOGY
- Regulatory T Cells and Immune Tolerance in the Intestine
- (2013) O. J. Harrison et al. Cold Spring Harbor Perspectives in Biology
- IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1/2
- (2013) Stéphanie Cochaud et al. Scientific Reports
- Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
- (2012) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Th17 and Th17-stimulated CD8+ T cells play a distinct role in Th17-induced preventive and therapeutic antitumor immunity
- (2011) Manjunatha Ankathatti Munegowda et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4
- (2011) O. S. Qureshi et al. SCIENCE
- Regulatory Lymphocytes and Intestinal Inflammation
- (2009) Ana Izcue et al. Annual Review of Immunology
- The Gut Mucosa as a Site for Induction of Regulatory T-Cells
- (2009) Meir Mizrahi et al. CURRENT PHARMACEUTICAL DESIGN
- T Helper 17 Cells Promote Cytotoxic T Cell Activation in Tumor Immunity
- (2009) Natalia Martin-Orozco et al. IMMUNITY
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
- (2009) Loise M. Francisco et al. JOURNAL OF EXPERIMENTAL MEDICINE
- CTLA4 blockade increases Th17 cells in patients with metastatic melanoma
- (2009) Erika von Euw et al. Journal of Translational Medicine
- Specific Microbiota Direct the Differentiation of IL-17-Producing T-Helper Cells in the Mucosa of the Small Intestine
- (2008) Ivaylo I. Ivanov et al. Cell Host & Microbe
- Allergy and the gastrointestinal system
- (2008) G. Vighi et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- ATP drives lamina propria TH17 cell differentiation
- (2008) Koji Atarashi et al. NATURE
- Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells
- (2008) L. Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started